The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.
An article from
The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.
Published July 17, 2026
Getty Images
Cash-strapped biotechnology company Jasper Therapeutics has gained a financial lifeline through a merger with a privately held immune drug developer.
Jasper Therapeutics (JSPR) acquires Kira Pharma & raises $132M, extending its cash runway into 2028. Shares surge 20%+.
Major M&A deals this week include: New Mountail Capital buys Asset Living, SalesForce acquires Contentful, Wellington nabs The…
Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly…
It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before…
Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a…
Lupin licenses two cancer drug programs to Kaveri Therapeutics for an $1.6 million stake, enhancing its oncology portfolio.
Jasper Closes Kira Deal, Extends Cash Runway - Jasper Therapeutics (NASDAQ:JSPR)
Lupin spins out two cancer drug programmes to new US venture for $1.6 million stake
Lupin takes 82.2% stake in Kaveri Therapeutics, licences 2 oncology assets for $1.6mn
Mirador unveils a piece of pipeline with drug from Kira to rival troubled Tavneos
